News for Curis, Inc. (CRIS)

H.C. Wainwright has initiated coverage on Curis (CRIS), assigning the company a Buy rating and setting a price target at $17. Curis, a biopharmaceutical company

Net Loss: $10.6 million or $1.25 per share for Q1 2025, compared to $11.9 million or $2.05 per share for Q1 2024.Research and Development Expenses: $8.5 millio

May 06, 2025 / 12:30PM GMTOperator Good morning, ladies and gentlemen, and welcome to the Curis provides first-quarter 2025 business update conference call. (Op

PR NewswireLEXINGTON, Mass., May 6, 2025 LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the d

Promising Study Results: Curis, Inc. showcases potential with significant findings in lymphoma and acute myeloid leukemia (AML) studies. Analyst Price T

Curis, Inc. (NASDAQ:CRIS) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ETCompany ParticipantsDiantha Duvall - Chief Financial OfficerJim Dentzer -...

PR NewswireLEXINGTON, Mass., May 6, 2025 Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer

Curis (CRIS) reported first-quarter revenue of $2.4 million, slightly below the expected $2.6 million. The company has enhanced its leadership team by appointin

Curis (CRIS) reduces net loss to $10.6 million in Q1 2025 from $11.9 million in Q1 2024. Emavusertib shows regulatory progress with FDA and EMA for acce

Curis Inc (CRIS) is set to release its Q1 2025 earnings on May 6, 2025. The consensus estimate for Q1 2025 revenue is $2.60 million, and the earnings are expect

PR NewswireLEXINGTON, Mass., April 2, 2025 LEXINGTON, Mass., April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on t

Discover key insights from Curis, Inc.'s Q4 2024 earnings call, highlighting promising trial results, regulatory alignment, and extended financial runway.

Curis, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ETCompany ParticipantsDiantha Duvall - CFOJim Dentzer - President and...

Curis (CRIS) reports Q4 GAAP EPS of -$1.25 and revenue growth of 24.5% YoY to $3.35M.

PR NewswireLEXINGTON, Mass., March 28, 2025 LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on

Recent Transaction Overview On December 31, 2024, Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, executed a significant stock transac

California-based clinical-stage biopharmaceutical company Revelation Biosciences, Inc. (REVB) is up over 125 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Curis Inc (CRIS) experienced a significant stock movement with a 6.19% increase in price, reaching $3.26 per share. The trading volume was 39,453 shares, with a

Curis stock plunges to 52-week low, hits $3.5 amid downturn